Hamburg Edoxaban for Anticoagulation in COVID-19 Study
NCT04542408
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
140
Enrollment
OTHER
Sponsor class
Conditions
Covid19
Interventions
DRUG:
Anticoagulation Agents (Edoxaban and/or high dose LMWH)
DRUG:
Low dose Low molecular weight heparin or Placebo
Sponsor
Universitätsklinikum Hamburg-Eppendorf